MUC1-C 是非小细胞肺癌获得性奥希替尼耐药的共同驱动因素
该研究在 H1975/EGFR(L858R/T790M)细胞、患者来源的 NSCLC 细胞及多种获得性奥希替尼耐药模型中,探讨 MUC1-C 对 EGFR 通路激活、克隆形成与自我更新能力的依赖性。结果显示 MUC1-C 在奥希替尼耐受持留细胞中上调,是耐药表型所必需,靶向 MUC1-C 可逆转耐药;高 MUC1 mRNA 与 MUC1-C 蛋白表达与 EGFR 突变 NSCLC 患者不良预后相关。
要点
- MUC1-C 在 H1975 奥希替尼药物耐受持留细胞中上调,为 EGFR 通路激活所必需。
- H1975-OR 与患者来源 MGH700-2D 等耐药细胞依赖 MUC1-C 诱导 p-EGFR、p-ERK、p-AKT、EMT 及耐药表型。
- 在 MET 扩增及 EGFR T790M/C797S 耐药模型中靶向 MUC1-C 可逆转奥希替尼耐药。
核心结论
- MUC1-C 是奥希替尼耐药的共同效应分子,并是治疗奥希替尼耐药 NSCLC 的潜在靶点。
研究设计与样本
- 研究在 H1975/EGFR(L858R/T790M)细胞和患者来源的 NSCLC 细胞中,围绕 MUC1-C 依赖性开展 EGFR 通路激活、克隆形成与自我更新能力的研究。
主要发现
- MUC1-C 在 H1975 奥希替尼药物耐受持留细胞中上调,且为 EGFR 通路激活所必需。
- H1975-OR 细胞与来自获得性奥希替尼耐药患者的 MGH700-2D 细胞依赖 MUC1-C 诱导 p-EGFR、p-ERK、p-AKT、EMT 及耐药表型。
- 在 MET 扩增的 MGH170-1D #2 细胞及 MGH121 Res#2/EGFR(T790M/C797S)细胞中,MUC1-C 也为 p-EGFR、p-ERK、p-AKT 激活与自我更新能力所必需。
- 在上述多种模型中靶向 MUC1-C 可逆转奥希替尼耐药。
- 高 MUC1 mRNA 与 MUC1-C 蛋白表达与 EGFR 突变 NSCLC 患者的不良预后相关。
临床怎么用
- 原文结论指出 MUC1-C 是奥希替尼耐药的共同效应分子,并是治疗奥希替尼耐药 NSCLC 的潜在靶点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Osimertinib is an irreversible EGFR tyrosine kinase inhibitor approved for the first-line treatment of patients with metastatic NSCLC harboring EGFR exon 19 deletions or L858R mutations. Patients treated with osimertinib invariably develop acquired resistance by mechanisms involving additional EGFR mutations, MET amplification, and other pathways. There is no known involvement of the oncogenic MUC1-C protein in acquired osimertinib resistance. METHODS: H1975/EGFR (L858R/T790M) and patient-derived NSCLC cells with acquired osimertinib resistance were investigated for MUC1-C dependence in studies of EGFR pathway activation, clonogenicity, and self-renewal capacity. RESULTS: We reveal that MUC1-C is up-regulated in H1975 osimertinib drug-tolerant persister cells and is necessary for activation of the EGFR pathway. H1975 cells selected for stable osimertinib resistance (H1975-OR) and MGH700-2D cells isolated from a patient with acquired osimertinib resistance are found to be dependent on MUC1-C for induction of (1) phospho (p)-EGFR, p-ERK, and p-AKT, (2) EMT, and (3) the resistant phenotype. We report that MUC1-C is also required for p-EGFR, p-ERK, and p-AKT activation and self-renewal capacity in acquired osimertinib-resistant (1) MET-amplified MGH170-1D #2 cells and (2) MGH121 Res#2/EGFR (T790M/C797S) cells. Importantly, targeting MUC1-C in these diverse models reverses osimertinib resistance. In support of these results, high MUC1 mRNA and MUC1-C protein expression is associated with a poor prognosis for patients with EGFR-mutant NSCLCs. CONCLUSIONS: Our findings reveal that MUC1-C is a common effector of osimertinib resistance and is a potential target for the treatment of osimertinib-resistant NSCLCs.
引用
- Haratake N, Ozawa H, Morimoto Y, et al. MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC. J Thorac Oncol. 2023. PMID: 37924972. doi:10.1016/j.jtho.2023.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。